University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Robert S. Warren, MD

Robert S. Warren, MD

Professor, Department of Surgery; Chief of Surgical Oncology, UCSF

Cancer Center Program Memberships

Affiliate Member

Education

Cornell University, Ithaca, NY, 1966-1967, English
Lawrence University, Appleton, Wisconsin, 1967-1968, Biology
Univ. of Minnesota, Minneapolis, MN, B.A., 1969-1971, Physiology
Grad. School, Univ. of Minnesota, Minneapolis, MN, 1971-1975, Cell Biology
Med. School, Univ. of Minnesota, Minneapolis, MN, M.D., 1976-1980, Medicine


Professional Experience

  •     1980-1983, 1986-1988
        Surgery Internship and Residency, University of Minnesota
  •     1983-1986
        Fellowship, Memorial Sloan-Kettering Cancer Center; NY, NY
  •     1984-1985
        Associate Physician, Rockefeller University; NY, NY
  •     1988-1994
        Assistant Professor, Department of Surgery, UCSF
  •     1994-present
        Associate Professor, Department of Surgery, UCSF
  •     2000-present
        Chief, Surgical Oncology, UCSF
  •     2000-present
        Professor, Department of Surgery, UCSF

Honors & Awards

  • 1971
    BA magna cum laude
  • 1980
    Alpha Omega Alpha Honorary Medical Society

Selected Publications

  1. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469.
    View on PubMed
  2. Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight. 2019 Jun 25; 5.
    View on PubMed
  3. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol. 2019 Mar; 12(3):550-560.
    View on PubMed
  4. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec; 17(12):2702-2709.
    View on PubMed
  5. Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ. Sampling strategies to capture single-cell heterogeneity. Nat Methods. 2017 Oct; 14(10):967-970.
    View on PubMed
  6. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22.
    View on PubMed
  7. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374.
    View on PubMed
  8. Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist. 2017 01; 22(1):107-114.
    View on PubMed
  9. Yazdany J, Myslinski R, Miller A, Francisco M, Desai S, Schmajuk G, Lacaille D, Barber CE, Orozco C, Bunyard M, Bergman MJ, Passo M, Matteson EL, Olson R, Silverman S, Warren R, Nola K, Robbins M. Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. Arthritis Care Res (Hoboken). 2016 10; 68(10):1402-9.
    View on PubMed
  10. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53.
    View on PubMed
  11. Depeille P, Warren RS, Roose JP. Unexpected insights for anti-EGFR cancer therapy. Oncotarget. 2015 Aug 07; 6(22):18746-7.
    View on PubMed
  12. Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015 Jun; 17(6):804-15.
    View on PubMed
  13. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45.
    View on PubMed
  14. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31(29):3664-72.
    View on PubMed
  15. Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817.
    View on PubMed
  16. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
    View on PubMed
  17. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506.
    View on PubMed
  18. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  19. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
    View on PubMed
  20. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):93-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI